RAPT Therapeutics
Biotechnology ResearchView the employees at
RAPT Therapeutics-
Shoji Ikeda Assoc. Dir. Clinical Sample Management at RAPT Therapeutics
-
San Francisco Bay Area
-
Top 10%
Linda Flemming Finance Manager at RAPt-
London, England, United Kingdom
-
Rising Star
Jigisha Shah, Ph.D. Senior Manager, Regulatory Affairs at Cytokinetics | Past Chair, Silicon Valley American Chemical Society-
San Francisco Bay Area
-
Top 5%
Nuno Albuquerque Senior Counsellor at RAPt-
Milton Keynes, England, United Kingdom
-
Rising Star
Denise de Almeida Nagata Clinical Biomarkers for Immunotherapy-
San Francisco Bay Area
-
Rising Star
Overview
RAPT Therapeutics is a clinical stage immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The company is also pursuing a range of targets that are in the discovery stage of development.
-